Long-term registries: Answering tough questions with big data?
作者信息
Fox Robert J, Cutter Gary
机构信息
Mellen Center for Multiple Sclerosis (RJF), Cleveland Clinic, OH; and Department of Biostatistics (GC), University of Alabama at Birmingham School of Public Health.
出版信息
Neurol Clin Pract. 2016 Apr;6(2):97-99. doi: 10.1212/CPJ.0000000000000226.
Abstract
摘要
相似文献
1
Long-term registries: Answering tough questions with big data?
Neurol Clin Pract. 2016 Apr;6(2):97-99. doi: 10.1212/CPJ.0000000000000226.
2
The opportunities and shortcomings of using big data and national databases for sarcoma research.
Cancer. 2019 Sep 1;125(17):2926-2934. doi: 10.1002/cncr.32118. Epub 2019 May 15.
3
Answering tough questions on interview.
Nurs Econ. 2000 Jan-Feb;18(1):45.
4
Answering the TOUGH ICD10 Questions.
J AHIMA. 2015 Jun;86(6):28-32.
5
From teachers to toxicologists: answering the tough questions about animal research.
Fundam Appl Toxicol. 1996 Nov;34(1):5-14. doi: 10.1006/faat.1996.0170.
6
Answering the hard questions: the Genetic Testing Registry and its request for information.
Genet Test Mol Biomarkers. 2011 Jan-Feb;15(1-2):1-2. doi: 10.1089/gtmb.2010.1516.
7
Answering big questions, and making hard decisions.
JAAPA. 2000 Mar;13(3):119-20.
8
Answering big questions, and making hard decisions.
JAAPA. 2000 Mar;13(3):120.
9
Answering unanswered questions: proposal for a shared resource in clinical diagnostic radiology research.
Radiology. 1992 Jun;183(3):619-20. doi: 10.1148/radiology.183.3.1584905.
10
A subgraph-representation-based method for answering complex questions over knowledge bases.
Neural Netw. 2019 Nov;119:57-65. doi: 10.1016/j.neunet.2019.07.014. Epub 2019 Jul 26.
引用本文的文献
1
Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: a cohort study based on German claims data.
Neuropsychiatr Dis Treat. 2019 May 28;15:1439-1457. doi: 10.2147/NDT.S200930. eCollection 2019.
2
Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study.
J Neurol. 2020 Feb;267(2):308-316. doi: 10.1007/s00415-018-09169-w. Epub 2019 Jan 4.
本文引用的文献
1
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.
Neurol Clin Pract. 2016 Apr;6(2):102-115. doi: 10.1212/CPJ.0000000000000227.
2
Comparative efficacy of switching to natalizumab in active multiple sclerosis.
Ann Clin Transl Neurol. 2015 Apr;2(4):373-87. doi: 10.1002/acn3.180. Epub 2015 Feb 27.
3
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1190-7. doi: 10.1136/jnnp-2013-306936. Epub 2014 Feb 14.
4
Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.
N Engl J Med. 2012 Sep 20;367(12):1098-107. doi: 10.1056/NEJMoa1114287.
5
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328.
Zotero 插件